FAQ: Kairos Pharma's Positive Phase 2 Data for ENV105 in Prostate Cancer
Summary
What is the main topic of this announcement?
Kairos Pharma announced positive interim efficacy data from its ongoing Phase 2 trial of ENV105 (carotuximab) in combination with apalutamide for metastatic castration-resistant prostate cancer, showing significant improvement in progression-free survival.
What were the key results from the Phase 2 trial?
Among eight evaluable patients, the combination achieved median progression-free survival of more than 13 months, with five patients still on treatment and seven of nine showing declines in prostate-specific antigen levels, exceeding the trial’s target of 45% improvement over standard therapy.
Why is this data significant for prostate cancer treatment?
This data is significant because it shows ENV105 may help overcome drug resistance in prostate cancer, with results substantially better than the standard 3.7 months progression-free survival for second- or third-line hormone therapy, addressing a major unmet medical need.
How does ENV105 work to treat cancer?
ENV105 is an antibody that targets CD105, a protein identified as a key driver of resistance to various cancer treatments. It aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types.
What is the safety profile of ENV105 based on this data?
The treatment was well tolerated with no dose-limiting toxicities observed in the Phase 2 trial, indicating a favorable safety profile for the ENV105 and apalutamide combination therapy.
Where can I find more detailed information about these results?
The full press release is available at https://ibn.fm/BSLuY, and Kairos Pharma is hosting a KOL webcast to review the findings with clinical experts. Additional updates are available in the company’s newsroom at https://ibn.fm/KAPA.
What other cancer types is ENV105 being tested for?
In addition to the Phase 2 trial for castrate-resistant prostate cancer, ENV105 is also in a Phase 1 clinical trial for lung cancer, demonstrating its potential application across multiple cancer types where drug resistance is a challenge.
When is the webcast to discuss these findings?
Kairos Pharma is hosting a KOL webcast today at 5 p.m. ET / 2 p.m. PT to review the interim Phase 2 findings with clinical experts in the field.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 212289